- Home
- INZY vs ABEO Comparison
INZY vs ABEO Comparison
Compare INZY & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- ABEO
- Stock Information
- Founded
- INZY 2015
- ABEO 1974
- Country
- INZY United States
- ABEO United States
- Employees
- INZY N/A
- ABEO N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- INZY Health Care
- ABEO Health Care
- Exchange
- INZY Nasdaq
- ABEO Nasdaq
- Market Cap
- INZY 255.3M
- ABEO 256.9M
- IPO Year
- INZY 2020
- ABEO 1980
- Fundamental
- Price
- INZY $3.99
- ABEO $5.93
- Analyst Decision
- INZY Buy
- ABEO Strong Buy
- Analyst Count
- INZY 9
- ABEO 6
- Target Price
- INZY $15.22
- ABEO $18.00
- AVG Volume (30 Days)
- INZY 1.3M
- ABEO 870.0K
- Earning Date
- INZY 08-05-2025
- ABEO 08-11-2025
- Dividend Yield
- INZY N/A
- ABEO N/A
- EPS Growth
- INZY N/A
- ABEO N/A
- EPS
- INZY N/A
- ABEO N/A
- Revenue
- INZY N/A
- ABEO N/A
- Revenue This Year
- INZY N/A
- ABEO N/A
- Revenue Next Year
- INZY N/A
- ABEO $323.51
- P/E Ratio
- INZY N/A
- ABEO N/A
- Revenue Growth
- INZY N/A
- ABEO N/A
- 52 Week Low
- INZY $0.72
- ABEO $3.93
- 52 Week High
- INZY $6.24
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- INZY 83.59
- ABEO 45.53
- Support Level
- INZY $3.94
- ABEO $6.10
- Resistance Level
- INZY $3.97
- ABEO $6.24
- Average True Range (ATR)
- INZY 0.01
- ABEO 0.29
- MACD
- INZY -0.10
- ABEO -0.09
- Stochastic Oscillator
- INZY 100.00
- ABEO 4.26
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.